Our top pick for
Cyren Ltd is a software-infrastructure business based in the US. Cyren shares (CYRN) are listed on the NASDAQ and all prices are listed in US Dollars. Cyren employs 343 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$0.48|
|52-week range||$0.46 - $1.60|
|50-day moving average||$0.55|
|200-day moving average||$0.63|
|Wall St. target price||$1.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.30|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||4.28%|
|1 month (2021-09-22)||-11.17%|
|3 months (2021-07-22)||-27.32%|
|6 months (2021-04-22)||-25.05%|
|1 year (2020-10-22)||-48.42%|
|2 years (2019-10-22)||-69.45%|
|3 years (2018-10-22)||3.24|
|5 years (2016-10-21)||2.31|
|Revenue TTM||$33.9 million|
|Gross profit TTM||$21.6 million|
|Return on assets TTM||-16.83%|
|Return on equity TTM||-111.51%|
|Market capitalisation||$41.3 million|
TTM: trailing 12 months
There are currently 4.0 million Cyren shares held short by investors – that's known as Cyren's "short interest". This figure is 75.1% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting Cyren shares can be evaluated.
Cyren's "short interest ratio" (SIR) is the quantity of Cyren shares currently shorted divided by the average quantity of Cyren shares traded daily (recently around 6.8 million). Cyren's SIR currently stands at 0.58. In other words for every 100,000 Cyren shares traded daily on the market, roughly 580 shares are currently held short.
However Cyren's short interest can also be evaluated against the total number of Cyren shares, or, against the total number of tradable Cyren shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cyren's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Cyren shares in existence, roughly 40 shares are currently held short) or 0.0922% of the tradable shares (for every 100,000 tradable Cyren shares, roughly 92 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cyren.
Find out more about how you can short Cyren stock.
We're not expecting Cyren to pay a dividend over the next 12 months.
Cyren's shares were split on a 1:3 basis on 1 January 2008. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cyren shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Cyren shares which in turn could have impacted Cyren's share price.
Over the last 12 months, Cyren's shares have ranged in value from as little as $0.46 up to $1.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyren's is 0.3402. This would suggest that Cyren's shares are less volatile than average (for this exchange).
Cyren Ltd. , together with its subsidiaries, develops and markets information security solutions for protecting Web, email, and mobile transactions in the United States, Germany, other European countries, the Asia Pacific, Israel, and internationally. It offers software-as-a-service (SaaS) cybersecurity solutions that protect businesses, their employees, and customers from email, files, and the web threats. The company provides Cyren threat detection services, which include email security engine that offers anti-spam inbound and outbound, IP reputation, and virus outbreak detection services; malware detection engine that is used to protect email applications; Web security engine that is used by customers to provide URL classification for web browser filtering and safe search capabilities; and threat analysis services to detect advanced cyber threats. It also provides Cyren threat intelligence data products, which include real-time phishing intelligence, malware file intelligence, IP reputation intelligence, malware URL intelligence, and Zombie host intelligence for threat detection, threat hunting, and incident response. In addition, the company offers Cyren enterprise email security products, including Cyren Email Security, a cloud-based secure email gateway; Cyren Inbox Security, an anti-phishing and remediation product for Microsoft 365; and Cyren Threat InDepth, a threat intelligence that allows enterprise security teams and executives to gain a view of evolving email-borne threats and make decisions to mitigate them. It sells its products through direct and indirect channels, including distributors, value added resellers, and managed service providers to enterprise customers and original equipment manufacturers.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.